Morton Brown Family Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Morton Brown Family Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$993	Buy	+2	New	+$886	﹤0.01%	312
2023 Q2	–	Sell	-7	Closed	-$2.21K	–	290
2023 Q1	$2.21K	Buy	+7	New	+$2.1K	﹤0.01%	187

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Morton Brown Family Wealth's VRTX Position: Q2 2026 in Review

Morton Brown Family Wealth opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 2 shares worth $993. The stake represents ﹤0.01% of the portfolio and ranks #312 among its holdings. This is a return to the name: Morton Brown Family Wealth previously reported a position in VRTX as recently as Q1 2023.

Morton Brown Family Wealth first reported a position in VRTX in Q1 2023 and has held it in 2 quarters since. The position peaked at $2.21K in Q1 2023. 484 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Morton Brown Family Wealth held 2 shares of Vertex Pharmaceuticals worth $993 as of Q2 2026.
Vertex Pharmaceuticals was a new Morton Brown Family Wealth position in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Morton Brown Family Wealth's portfolio in Q2 2026, its #312 holding.
Morton Brown Family Wealth first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 2 quarters since.
Morton Brown Family Wealth's Vertex Pharmaceuticals position peaked at $2.21K in Q1 2023.
484 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Morton Brown Family Wealth's 13F filing for Q2 2026, filed 21 Jul 2026.